In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roivant Sciences raises $200mm in private placement

Executive Summary

Roivant Sciences GMBH raised $200mm in a private placement financing ($7bn post-money valuation) with new investors NovaQuest Capital Management, RTW Investments and other large institutional asset managers. All previous institutional shareholders also participated in the financing. The company will use the offering proceeds to launch additional "Vants" (entrepreneurial biotech and healthcare tech companies) for innovative medicines and technologies. Since Roivant's last financing in 2017, the company has grown its therapies in development from 14 to 34 and its Vants from 6 to 14.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

UsernamePublicRestriction

Register